Effect of MPTP on mRNA expression of PGC-1α in mouse brain

The peroxisome proliferator-activated receptor-γ (PPARγ) coactivator 1α (PGC-1α) is a key regulator of mitochondrial biogenesis, respiration and adaptive thermogenesis. Besides the full-length protein (FL-PGC-1α), several other functionally active PGC-1α isoforms were identified as a result of alter...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Török Rita
Salamon András
Sümegi Evelin
Zádori Dénes
Veres Gábor
Fort Molnár Máté
Vécsei László
Klivényi Péter
Dokumentumtípus: Cikk
Megjelent: Elsevier 2017
Sorozat:BRAIN RESEARCH 1660
doi:10.1016/j.brainres.2017.01.032

mtmt:3192889
Online Access:http://publicatio.bibl.u-szeged.hu/11712
LEADER 02901nab a2200301 i 4500
001 publ11712
005 20191128103516.0
008 170705s2017 hu o 0|| zxx d
022 |a 0006-8993 
024 7 |a 10.1016/j.brainres.2017.01.032  |2 doi 
024 7 |a 3192889  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a zxx 
100 1 |a Török Rita 
245 1 0 |a Effect of MPTP on mRNA expression of PGC-1α in mouse brain  |h [elektronikus dokumentum] /  |c  Török Rita 
260 |a Elsevier  |c 2017 
300 |a 20-26 
490 0 |a BRAIN RESEARCH  |v 1660 
520 3 |a The peroxisome proliferator-activated receptor-γ (PPARγ) coactivator 1α (PGC-1α) is a key regulator of mitochondrial biogenesis, respiration and adaptive thermogenesis. Besides the full-length protein (FL-PGC-1α), several other functionally active PGC-1α isoforms were identified as a result of alternative splicing (e.g., N-truncated PGC-1α; NT-PGC-1α) or alternative promoter usage (e.g., central nervous system-specific PGC-1α isoforms; CNS-PGC-1α). Achieving neuroprotection via CNS-targeted pharmacological stimulation is limited due to poor penetration of the blood brain barrier (BBB) by the proposed pharmaceutical agents, so preconditioning emerged as another option. The current study aimed to examine of how the expression levels of FL-, NT-, CNS- and reference PGC-1α isoforms change in different brain regions following various 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment regimens, including chronic low-dose treatment for preconditioning. Ninety minutes following the acute treatment regimen, the expression levels of FL-, NT- and CNS-PGC-1α isoforms increased significantly in the striatum, cortex and cerebellum. However, this elevation diminished 7 days following the last MPTP injection in the acute treatment regimen. The chronic low-dose administration of MPTP, which did not cause significant toxic effects in light of the relatively unaltered dopamine levels, did not result in any significant change of PGC-1α expression. The elevation of PGC-1α levels following acute treatment may demonstrate a short-term compensatory mechanism against mitochondrial damage induced by the complex I inhibitor MPTP. However, drug-induced preconditioning by chronic low-dose MPTP seems not to induce protective responses via the PGC-1α system. © 2017 Elsevier B.V. 
700 0 1 |a Salamon András  |e aut 
700 0 1 |a Sümegi Evelin  |e aut 
700 0 1 |a Zádori Dénes  |e aut 
700 0 1 |a Veres Gábor  |e aut 
700 0 2 |a Fort Molnár Máté  |e aut 
700 0 2 |a Vécsei László  |e aut 
700 0 2 |a Klivényi Péter  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/11712/1/Effect_of_MPTP_on_mRNA_expression_of_PGC_1_in_mouse_brain_u.pdf  |z Dokumentum-elérés  
856 4 0 |u http://publicatio.bibl.u-szeged.hu/11712/7/Brain_Research_2017_1660_editoral_board.pdf  |z Dokumentum-elérés